Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Income from Non-Controlling Interests (2016 - 2025)

vTv Therapeutics' Income from Non-Controlling Interests history spans 11 years, with the latest figure at -$1.6 million for Q3 2025.

  • For Q3 2025, Income from Non-Controlling Interests fell 55.82% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached -$4.1 million, up 3.23%, while the annual FY2025 figure was -$4.1 million, 3.23% up from the prior year.
  • Income from Non-Controlling Interests for Q3 2025 was -$1.6 million at vTv Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$233000.0 in Q2 2021 and bottomed at -$2.4 million in Q4 2021.
  • The 5-year median for Income from Non-Controlling Interests is -$1.2 million (2024), against an average of -$1.3 million.
  • The largest YoY upside for Income from Non-Controlling Interests was 85.64% in 2021 against a maximum downside of 605.61% in 2021.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$2.4 million in 2021, then skyrocketed by 44.7% to -$1.3 million in 2022, then increased by 28.4% to -$963000.0 in 2023, then rose by 16.61% to -$803000.0 in 2024, then crashed by 105.11% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Income from Non-Controlling Interests are -$1.6 million (Q3 2025), -$1.3 million (Q2 2025), and -$1.1 million (Q1 2025).